NICE TAs

24/09/2026

TA1194: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

23/09/2026

TA1193: Ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable

16/09/2026

TA1192: Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years

09/09/2026

TA1191: Nemolizumab for treating moderate to severe prurigo nodularis

09/09/2026

TA1190: Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer

26/08/2026

TA1189: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

25/08/2026

TA1188: Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over (terminated evaluation)

21/08/2026

TA1187: Rilzabrutinib for treating persistent or chronic immune thrombocytopenia (terminated evaluation)

21/08/2026

TA1186: Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation)

19/08/2026

TA1185: Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia

19/08/2026

TA1184: Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma

19/08/2026

TA1183: Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over

05/08/2026

TA1182: Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction

30/07/2026

TA1181: Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy

16/07/2026

TA1179: Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane (terminated evaluation)

16/07/2026

TA1180: Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation)

15/07/2026

TA1178: Deuruxolitinib for treating severe alopecia areata

14/07/2026

TA1177: Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer

09/07/2026

TA1176: Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes

09/07/2026

TA1175: Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis